The drug, vercirnon, relieved patients’ moderate-to-severe Chrohn’s symptoms no more than the placebo treatments. The study involved 608 patients who were given the treatment for three months.
Company executives expressed disappointment with the results, and GSK will revisit the drug’s development program.
More Articles on Gastroenterology:
Endoscopic Surveillance of Barrett’s Esophagus Not Linked With Cancer Survival
Bariatric Surgery Does Not Reduce Long Term Healthcare Costs, Study Says
EndoChoice’s Fuse System Cuts Down on Missed Colon Adenomas, Study Shows
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.